GSTM1 and chronic kidney disease: In the NDD-CKD study, a double-blind, placebo-controlled 8-week portion of a 26-week study, 151 participants (mean Hb 8.9 g/dl at baseline) were randomized 2:1 to receive roxadustat (n = 101) or placebo (n = 50) [52].